Russell Investments Group Ltd. acquired a new stake in shares of Ampio Pharmaceuticals Inc (NYSEAMERICAN:AMPE) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 433,776 shares of the specialty pharmaceutical company’s stock, valued at approximately $220,000. Russell Investments Group Ltd. owned about 0.41% of Ampio Pharmaceuticals as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Courier Capital LLC raised its stake in Ampio Pharmaceuticals by 2,032.7% during the 3rd quarter. Courier Capital LLC now owns 304,973 shares of the specialty pharmaceutical company’s stock valued at $155,000 after acquiring an additional 290,673 shares during the last quarter. Northern Trust Corp raised its stake in shares of Ampio Pharmaceuticals by 507.8% during the 2nd quarter. Northern Trust Corp now owns 850,903 shares of the specialty pharmaceutical company’s stock worth $1,872,000 after buying an additional 710,911 shares in the last quarter. Valeo Financial Advisors LLC purchased a new position in shares of Ampio Pharmaceuticals during the 2nd quarter worth approximately $155,000. BlackRock Inc. raised its stake in shares of Ampio Pharmaceuticals by 318.3% during the 2nd quarter. BlackRock Inc. now owns 5,153,537 shares of the specialty pharmaceutical company’s stock worth $11,339,000 after buying an additional 3,921,550 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. purchased a new position in shares of Ampio Pharmaceuticals during the 2nd quarter worth approximately $326,000.
Shares of AMPE stock traded down $0.01 during trading hours on Thursday, reaching $0.43. 650,500 shares of the company’s stock were exchanged, compared to its average volume of 691,950. Ampio Pharmaceuticals Inc has a 1 year low of $0.35 and a 1 year high of $3.89.
Ampio Pharmaceuticals Company Profile
Ampio Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of therapies for the treatment of prevalent inflammatory conditions in the United States. The company is developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; activating specific phosphatase or depleting available phosphate needed for the inflammation process; and decreasing vascular permeability.
Recommended Story: What is the NASDAQ?